A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125 in HIV-1 Infected Subjects With Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations

Trial Profile

A Randomized, Controlled, Partially Blinded Phase IIb Dose-Finding Trial of TMC125 in HIV-1 Infected Subjects With Documented Genotypic Evidence of Resistance to Currently Available NNRTIs and With at Least Three Primary PI Mutations

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2010

At a glance

  • Drugs Etravirine (Primary)
  • Indications HIV infections; HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Janssen R&D Ireland
  • Most Recent Events

    • 21 Jul 2009 Actual patient number changed from 199 to 211 as reported by ClinicalTrials.gov.
    • 10 Mar 2009 New trial record.
    • 28 Jan 2009 Results were published in AIDS.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top